Imatinib Mesylate Inhibits Glucose Uptake in Gastrointestinal Stromal Tumor Cells by Downregulation of the Glucose Transporters Recruitment to the Plasma Membrane
暂无分享,去创建一个
Luc Mortelmans | Sigrid Stroobants | Patrick Schöffski | Bart Landuyt | Hans Prenen | Peter Vermaelen | L. Mortelmans | M. Bollen | M. Debiec‐Rychter | R. Sciot | S. Stroobants | P. Schöffski | B. Landuyt | H. Prenen | P. Vermaelen | A. Oosterom | Mathieu Bollen | E. Bruijn | Maria Debiec-Rychter | Christiana Stefan | Ernst A. de Bruijn | Raphael Sciot | Allan T. van Oosterom | C. Stefan | M. Debiec-Rychter | Peter Vermaelen
[1] T. Churchill,et al. 5-aminoimidazole-4-carboxamide riboside (AICAR) enhances GLUT2-dependent jejunal glucose transport: a possible role for AMPK. , 2005, The Biochemical journal.
[2] J. Affleck,et al. Immunocytochemical Detection of GLUT2 at the Rat Intestinal Brush-border Membrane , 2003, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.
[3] John E. Murphy,et al. A new acute transforming feline retrovirus and relationship of its oncogene v-kit with the protein kinase gene family , 1986, Nature.
[4] C. J. Chen,et al. KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. , 2001, Cancer research.
[5] J. Baselga,et al. Expression of the fructose transporter GLUT5 in human breast cancer. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[6] M Cascante,et al. Gleevec (STI571) influences metabolic enzyme activities and glucose carbon flow toward nucleic acid and fatty acid synthesis in myeloid tumor cells. , 2001, The Journal of biological chemistry.
[7] J. Fletcher,et al. Biology of gastrointestinal stromal tumors. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] F. Ismail-Beigi,et al. Regulation of glucose transport by hypoxia. , 1999, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[9] S. Gottschalk,et al. Imatinib (STI571)-Mediated Changes in Glucose Metabolism in Human Leukemia BCR-ABL-Positive Cells , 2004, Clinical Cancer Research.
[10] C. March,et al. Identification of a ligand for the c-kit proto-oncogene , 1990, Cell.
[11] Sigrid Stroobants,et al. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study , 2001, The Lancet.
[12] H. Friess,et al. Effects of STI571 (gleevec) on pancreatic cancer cell growth , 2003, Molecular Cancer.
[13] B. Druker,et al. Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. , 2000, Blood.
[14] Ping Huang,et al. The role of phospholipase D in Glut‐4 translocation , 2003, Diabetes/metabolism research and reviews.
[15] A. D. Van den Abbeele,et al. Use of positron emission tomography in oncology and its potential role to assess response to imatinib mesylate therapy in gastrointestinal stromal tumors (GISTs). , 2002, European journal of cancer.
[16] D. N. Gross,et al. Glut4 Storage Vesicles without Glut4: Transcriptional Regulation of Insulin-Dependent Vesicular Traffic , 2004, Molecular and Cellular Biology.
[17] J. Fletcher,et al. KIT extracellular and kinase domain mutations in gastrointestinal stromal tumors. , 2000, The American journal of pathology.
[18] L. Landi,et al. Stem cell factor and H2O2 induce GLUT1 translocation in M07e cells , 2004, BioFactors.
[19] A. D. Van den Abbeele,et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. , 2002, The New England journal of medicine.
[20] C. Cheeseman,et al. Rapid insertion of GLUT2 into the rat jejunal brush-border membrane promoted by glucagon-like peptide 2. , 2002, The Biochemical journal.
[21] T. Jacks,et al. STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications , 2001, Oncogene.
[22] S. Hirota,et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. , 1998, Science.
[23] K. Dimitriadis,et al. Optimization of the sulforhodamine B colorimetric assay. , 1997, Journal of immunological methods.
[24] J Nuyts,et al. 18FDG-Positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec). , 2003, European journal of cancer.
[25] D. Scudiero,et al. New colorimetric cytotoxicity assay for anticancer-drug screening. , 1990, Journal of the National Cancer Institute.
[26] L. Sobin,et al. Diagnosis of gastrointestinal stromal tumors: A consensus approach. , 2002, Human pathology.
[27] T. Nishida,et al. Gain‐of‐function mutation at the extracellular domain of KIT in gastrointestinal stromal tumours , 2001, The Journal of pathology.
[28] G. Demetri,et al. Serum KIT and KIT ligand levels in patients with gastrointestinal stromal tumors treated with imatinib , 2004 .
[29] C. Sawyers,et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. , 2001, The New England journal of medicine.
[30] P. Åman,et al. The complexity of KIT gene mutations and chromosome rearrangements and their clinical correlation in gastrointestinal stromal (pacemaker cell) tumors. , 2002, The American journal of pathology.